Latest news with #ArcusBiosciences
Yahoo
a day ago
- Business
- Yahoo
Jim Cramer on Arcus Biosciences: 'Let This Be Your Speculation'
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the stocks Jim Cramer shed light on. When a caller asked about the company during the lightning round, Cramer said: 'I'm of two minds here. Here's the problem. One is, is that they're losing a lot of money. But second, there's room for one speculation in everybody's portfolio. Let this be your speculation. But if you do this, you have to promise me that the other stocks are not going to be speculative because it's too risky to just bank it all on Arcus. Too risky.' Photo by Adam Nowakowski on Unsplash Arcus Biosciences, Inc. (NYSE:RCUS) is a clinical-stage biopharmaceutical company developing cancer therapies, including antibodies and small-molecule inhibitors targeting various tumor pathways. The company's pipeline addresses multiple cancers, such as lung, kidney, pancreatic, and colorectal. On August 6, Arcus Biosciences, Inc. (NYSE:RCUS) reported revenue of $160 million, which was up over 310% year-over-year. The company closed the June quarter with cash, cash equivalents, and marketable securities of $927 million compared to $992 million at the end of the December 2024 quarter. While we acknowledge the potential of RCUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
CNBC
4 days ago
- Business
- CNBC
Lightning Round: Arcus Biosciences is speculative, it's too risky to fully bank on, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Arcus Biosciences and Uranium Energy.
CNBC
4 days ago
- Business
- CNBC
Cramer's Lightning Round: Uranium Energy is a buy
Arcus Biosciences: "...Let this be your speculation. But if you do this, you have to promise me that the other stocks are not going to be speculative. Because it's too risky to just bank it all on Arcus." Uranium Energy: "I like nuclear. [buy, buy, buy!]" Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest
Business Insider
04-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
Business Insider
02-06-2025
- Business
- Business Insider
Arcus Biosciences presented data for casdatifan plus cabozantinib
Arcus Biosciences (RCUS) presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Arcus is pursuing a broad development program in both the immuno-oncology-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Confident Investing Starts Here:
